Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.6.1.3 (
ATPase
)
65,361
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In Escherichia coli, the molecular chaperones (DnaK, DnaJ, and GrpE) are essential for the rapid degradation of certain proteins. To see if chaperones are involved more generally in proteolysis, we studied the degradation of a short-lived fusion protein,
CRAG
, which associates with DnaK and GroEL in vivo. Its rapid degradation requires ATP and ClpP, the proteolytic subunit of protease Ti (Clp). However, this process is not reduced in strains lacking the complementary
ATPase
subunit, ClpA, or its homologs, ClpB and ClpX. At 37 degrees C, but not at 42 degrees C, protease La also contributes partially to
CRAG
degradation. Nevertheless,
CRAG
is not degraded in cell-free extracts or upon incubation with ClpP or protease La. We tested whether the chaperones associated with
CRAG
might be involved in its degradation.
CRAG
breakdown was accelerated 2-3-fold in strains with high levels of heat-shock proteins (hsps), i.e. in those that overproduce the hsp transcription factor (sigma 32) or carry a dnaK deletion. A similar stimulation of proteolysis was observed in cells overproducing GroEL or both GroEL and GroES; in these cells, more
CRAG
was associated with GroEL than in the wild type. In a temperature-sensitive groEL44 mutant at the nonpermissive temperature,
CRAG
breakdown was accelerated, and more
CRAG
was found complexed with GroEL. However, in a temperature-sensitive groES mutant,
CRAG
was completely stable at the nonpermissive temperature and accumulated bound to GroEL. These findings indicate that the association of
CRAG
with GroEL is a rate-limiting step in
CRAG
degradation, which also requires a subsequent action of GroES. We propose that if the hsp60/hsp10 chaperonins fail to catalyze the proper folding of a protein, they can facilitate its rapid degradation.
...
PMID:Rapid degradation of an abnormal protein in Escherichia coli involves the chaperones GroEL and GroES. 791 44
Polyglutamine diseases are inherited neurodegenerative diseases caused by the expanded polyglutamine proteins (polyQs). We have identified a novel guanosine
triphosphatase
(GTPase) named
CRAG
that contains a nuclear localization signal (NLS) sequence and forms nuclear inclusions in response to stress. After ultraviolet irradiation,
CRAG
interacted with and induced an enlarged ring-like structure of promyelocytic leukemia protein (PML) body in a GTPase-dependent manner. Reactive oxygen species (ROS) generated by polyQ accumulation triggered the association of
CRAG
with polyQ and the nuclear translocation of the
CRAG
-polyQ complex. Furthermore,
CRAG
promoted the degradation of polyQ at PML/
CRAG
bodies through the ubiquitin-proteasome pathway.
CRAG
knockdown by small interfering RNA in neuronal cells consistently blocked the nuclear translocation of polyQ and enhanced polyQ-mediated cell death. We propose that
CRAG
is a modulator of PML function and dynamics in ROS signaling and is protectively involved in the pathogenesis of polyglutamine diseases.
...
PMID:A novel GTPase, CRAG, mediates promyelocytic leukemia protein-associated nuclear body formation and degradation of expanded polyglutamine protein. 1646 59
Polyglutamine disorders are inherited neurodegenerative diseases caused by the accumulation of expanded polyglutamine protein (polyQ). Previously, we identified a new guanosine
triphosphatase
,
CRAG
, which facilitates the degradation of polyQ aggregates through the ubiquitin-proteasome pathway in cultured cells. Because expression of
CRAG
decreases in the adult brain, a reduced level of
CRAG
could underlie the onset of polyglutamine diseases. To examine the potential of
CRAG
expression for treating polyglutamine diseases, we generated model mice expressing polyQ predominantly in Purkinje cells. The model mice showed poor dendritic arborization of Purkinje cells, a markedly atrophied cerebellum and severe ataxia. Lentivector-mediated expression of
CRAG
in Purkinje cells of model mice extensively cleared polyQ aggregates and re-activated dendritic differentiation, resulting in a striking rescue from ataxia. Our in vivo data substantiate previous cell-culture-based results and extend further the usefulness of targeted delivery of
CRAG
as a gene therapy for polyglutamine diseases.
...
PMID:Lentivector-mediated rescue from cerebellar ataxia in a mouse model of spinocerebellar ataxia. 1834 73